MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-22-3929

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.

Letson Christopher T, Balasis Maria E, Newman Hannah, Binder Moritz, Vedder Alexis, Kinose Fumi, Ball Markus, Kruer Traci, Quintana Ariel, Lasho Terra L, Finke Christy M, Almada Luciana L, Grants Jennifer M, Zhang Guolin, Fernandez-Zapico Martin E, Gaspar-Maia Alexandre, Lancet Jeffrey, Komrokji Rami, Haura Eric, Sallman David A, Reuther Gary W, Karsan Aly, Rix Uwe, Patnaik Mrinal M, Padron Eric

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

PURPOSE: Preclinical studies in myeloid neoplasms have demonstrated efficacy of bromodomain and extra-terminal protein inhibitors (BETi). However, BETi demonstrates poor single-agent activity in clinical trials. Several studies suggest that combination with other anticancer inhibitors may enhance the efficacy of BETi.

EXPERIMENTAL

DESIGN

To nominate BETi combination therapies for myeloid neoplasms, we used a chemical screen with therapies currently in clinical cancer development and validated this screen using a panel of myeloid cell line, heterotopic cell line models, and patient-derived xenograft models of disease. We used standard protein and RNA assays to determine the mechanism responsible for synergy in our disease models.

RESULTS

We identified PIM inhibitors (PIMi) as therapeutically synergistic with BETi in myeloid leukemia models. Mechanistically, we show that PIM kinase is increased after BETi treatment, and that PIM kinase upregulation is sufficient to induce persistence to BETi and sensitize cells to PIMi. Furthermore, we demonstrate that miR-33a downregulation is the underlying mechanism driving PIM1 upregulation. We also show that GM-CSF hypersensitivity, a hallmark of chronic myelomonocytic leukemia (CMML), represents a molecular signature for sensitivity to combination therapy.

CONCLUSIONS

Inhibition of PIM kinases is a potential novel strategy for overcoming BETi persistence in myeloid neoplasms. Our data support further clinical investigation of this combination.

Для цитирования: Letson Christopher T, Balasis Maria E, Newman Hannah, Binder Moritz, Vedder Alexis, Kinose Fumi, Ball Markus, Kruer Traci, Quintana Ariel, Lasho Terra L, Finke Christy M, Almada Luciana L, Grants Jennifer M, Zhang Guolin, Fernandez-Zapico Martin E, Gaspar-Maia Alexandre, Lancet Jeffrey, Komrokji Rami, Haura Eric, Sallman David A, Reuther Gary W, Karsan Aly, Rix Uwe, Patnaik Mrinal M, Padron Eric. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023. DOI: 10.1158/1078-0432.ccr-22-3929.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.